Slow Capital Inc. Buys 16,117 Shares of Repligen Corporation (NASDAQ:RGEN)

Slow Capital Inc. grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 96.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,877 shares of the biotechnology company’s stock after acquiring an additional 16,117 shares during the quarter. Slow Capital Inc.’s holdings in Repligen were worth $4,183,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in RGEN. Proficio Capital Partners LLC purchased a new position in shares of Repligen during the fourth quarter worth approximately $3,066,000. Swiss National Bank raised its stake in shares of Repligen by 0.9% during the fourth quarter. Swiss National Bank now owns 104,700 shares of the biotechnology company’s stock worth $15,071,000 after acquiring an additional 900 shares in the last quarter. Natixis Advisors LLC raised its stake in shares of Repligen by 31.8% during the fourth quarter. Natixis Advisors LLC now owns 44,317 shares of the biotechnology company’s stock worth $6,379,000 after acquiring an additional 10,692 shares in the last quarter. CBIZ Investment Advisory Services LLC purchased a new position in shares of Repligen during the fourth quarter worth approximately $58,000. Finally, Polen Capital Management LLC increased its stake in shares of Repligen by 14.6% in the fourth quarter. Polen Capital Management LLC now owns 40,556 shares of the biotechnology company’s stock worth $5,838,000 after buying an additional 5,173 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several analyst reports. Evercore ISI decreased their target price on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 8th. JPMorgan Chase & Co. decreased their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Royal Bank Of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Finally, Barclays initiated coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $170.75.

Repligen Stock Down 2.8%

Shares of Repligen stock opened at $130.19 on Monday. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $125.65 and its two-hundred day simple moving average is $139.29. The company has a market cap of $7.31 billion, a P/E ratio of -289.31, a PEG ratio of 3.73 and a beta of 1.11. Repligen Corporation has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.28 EPS. Research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.